Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Limoges – page 5

469 clinical trials in Limoges, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Limoges at a glance
469
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

469 trials in Limoges

Open in trial search

Triple negative breast cancer

Recruiting

Testing sacituzumab govitecan and trastuzumab deruxtecan in alternating pattern for patients with HER2-low triple-negative breast cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sacituzumab Govitecan
  • Sponsor:Unicancer

Colorectal adenocarcinoma

Recruiting

Study of bevacizumab and trifluridine combination given bi-weekly to reduce severe neutropenia in patients with metastatic colorectal cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Association Gercor

Adenocarcinoma pancreas

Recruiting

Study of Gemcitabine with Paclitaxel versus Standard Chemotherapy Combination for Patients with Borderline Resectable Pancreatic Cancer Based on Gene Analysis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Fondation Franc.Cancerologie Digestive

Small cell lung cancer recurrent

Recruiting

Study comparing GSK5764227 and topotecan in adults with relapsed small cell lung cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:GSK5764227
  • Sponsor:Glaxosmithkline Research & Development Limited

Pulmonary arterial hypertension

Recruiting

Study comparing tadalafil with ambrisentan versus tadalafil alone in newly diagnosed patients with pulmonary arterial hypertension who have cardiovascular conditions

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ambrisentan
  • Sponsor:Assistance Publique Hopitaux De Paris

Chronic hepatitis B

Recruiting

Study comparing ALG-000184 with tenofovir disoproxil in untreated adults with chronic hepatitis B virus infection

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ALG-000184
  • Sponsor:Aligos Therapeutics Inc.

IgA nephropathy

Recruiting

Study of Mezagitamab in Adults with Primary IgA Nephropathy (Berger's Disease) to Reduce Protein in Urine

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Mezagitamab
  • Sponsor:Takeda Development Center Americas Inc.

K-ras gene mutation+1

Recruiting

Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Triple negative breast cancer

Recruiting

Evaluating sacituzumab tirumotecan alone or with pembrolizumab compared to standard treatment in untreated patients with metastatic triple-negative breast cancer with low PD-L1 expression

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Gastroenteropancreatic neuroendocrine tumour disease+1

Recruiting

Comparing tarlatamab with standard chemotherapy in patients with pre-treated advanced pulmonary or gastroenteropancreatic neuroendocrine carcinomas

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Haematological malignancy

Recruiting

Study of Reduced Cyclophosphamide Dose After Haploidentical Stem Cell Transplantation in Patients with Blood Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Assistance Publique Hopitaux De Paris

Non-small cell lung cancer

Recruiting

Study of WSD0922-FU for Patients with Advanced Non-Small Cell Lung Cancer and C797S Mutation After Osimertinib Treatment

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Wayshine Biopharm Inc.

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Limoges

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on multiple myeloma treatments and novel therapies for various cancers. Current trials investigate innovative approaches for colorectal cancer and esophageal squamous cell carcinoma.

  • Multiple Myeloma Treatment Optimization
  • Advanced Biliary Tract Cancer Therapy
  • Breast Cancer Treatment Innovation

Studies are evaluating new combination therapies and maintenance treatments to improve patient outcomes.

02 Neurological Disorders

Critical research into Amyotrophic Lateral Sclerosis (ALS) treatments, testing new therapeutic compounds and combinations to slow disease progression.

  • ALS Treatment Development
  • Novel Drug Combinations
  • Disease Progression Management

Multiple trials are exploring innovative approaches to improve quality of life for ALS patients.

03 Immunology and Transplantation

Advanced research in kidney transplantation and immune-related conditions, including studies on preventing rejection and managing immunosuppression.

  • Transplant Rejection Prevention
  • Immunotherapy Developments
  • Infection Prevention Strategies

Innovative approaches to improve transplant outcomes and manage immune system responses.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.